Login / Signup

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone.

Petr VokurkaAndrew BarronSheetal SumariaLindsey StockfordPaul JarmanKailash P BhatiaSimon FarmerTabish SaifeeTom WarnerRimona Sharon WeilSonia GandhiPatricia LimousinPrasad KorliparaThomas Foltynie
Published in: Movement disorders clinical practice (2020)
We conclude that opicapone can be an effective additional treatment for wearing off in Parkinson's disease (PD) in a subgroup of patients. The use of opicapone in our cohort with prior entacapone exposure, however, was associated with higher rates of adverse effects and treatment discontinuation than reported in published trial data of COMT inhibitor naïve patients.
Keyphrases